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The proposed Investment Committee Paper focuses on a potential Leveraged Buyout of Select Medical Holdings Corp, a key company of the United States healthcare
industry operating in Critical Illness Recovery Hospitals, Rehabilitation Hospitals, Outpatient Rehabilitation Clinics and Occupational Health Centers. The group initiated
a company and market overview to assess the eligibility of Select Medical as an LBO candidate. Future value creation strategies were developed and taken into
consideration in the forecast of the operating model. Posteriorly, the group evaluated the company, built an optimal capital structure and assessed potential exit
options, calculating the returns for the exit year.
Disclaimer:
Private Equity, LBO, Select Medical, Physical Therapy
The following Work Project was elaborated by a group a students from the Master in Finance from NOVA School of Business and Economics. We solemnly pledge that
the presented Work Project was done accordingly to the University’s Code of Honor, being entirely our own. This Investment Committee Paper was developed for
academic purposes only thus we do not take any responsibility for legal, investment or other decisions built upon this paper. The data used on the Work Project was
completely gathered from publicly available sources.
The Work Project is composed by three interdependent parts, as such, for a complete understanding of the Investment Committee Paper, please refer to “Select
Medical Holdings Corp – Private Equity Buyout” and “Select Medical Holdings Corp – Leveraged Buyout”.
This work used infrastructure and resources funded by Fundação para a Ciência e a Tecnologia (UID/ECO/00124/2013, UID/ECO/00124/2019 and Social Sciences
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Company Overview | Information on SEM’s Business Segments
Nova School of Business and Economics | Private Equity ChallengeSelect Medical Holdings 
SEM thrives with an adaptive business model that attracts many but different needs’ patients
4
Patients requiring occupational 
medicine/therapy consumer health 
services, focused on the health of 
America’s workforce
Source: Select Medical’s Annual Report 2019 and website, Bloomberg
Rehabilitation Hospitals Outpatient Rehabilitation Clinics Occupational Health CentersCritical Illness Recovery Hospitals
Patients that require physical, 
occupational and speech 
rehabilitation
Patients that require intensive physical 
rehabilitation care to rebuild function
Patients recovering from critical and 














68% Occupancy Rate 76% Occupancy Rate 8,719,282 Visits 12,068,865 Visits
1st Admission into one of CIRHs,
which ensures patient’s needs are met
2nd Full assessment of the patient by
specialized health care professionals
3rd Ongoing care and recovery
supported by daily physician rounds
Concentra offers occupational health
services to employers and respective
workforce, at the workplace or at a
clinic, to maintain its health and
safeguard, while reducing the overall













Net Revenue per 
Patient Day
Net Revenue per 
Patient Day
Net Revenue per 
Visit
Net Revenue per 
Visit
SEM's competitive position is affected by its ability of negotiating contracts with payors and, therefore, its prices can vary and rely on such agreements. The nature of
the firm’s industry and a highly fragmented market lead to competition between healthcare providers, giving payors significant influence and negotiating power.
However, Select Medical’s size and national presence, allow for strong bargaining power as well.
34% of Total Revenues & 101 Locations 12% of Total Revenues & 29 Locations 
19% of Total Revenues & 1740 
Locations 
30% of Total Revenues & 521 
Locations 
1st Referral to one of RHs, followed by
assessment of care needed
2nd Care team evaluation to create a
custom rehabilitative plan
3rd Treatment supported by healthcare
workers to maximize independence
1st Initial evaluation by therapist who
proposes an individual treatment plan
2nd Regularly scheduled appointments
with a clinical member
3rd Treatment supported by healthcare
workers to maximize independence
Attracting clients through 3 channels: word of mouth (based on SEM’s reputation), doctors’ referral and private and public insurance programs agreements
Nova School of Business and Economics | Private Equity ChallengeSelect Medical Holdings 
5
Historical Financial Analysis | Income Statement
Acquisitions have been contributing and improving operational performance at Select Medical
Income Statement in $M 2015 2016 2017 2018 2019
Critical Illness Recovery Hospital 1 903 1 757 1 725 1 754 1 837
Rehabilitation Hospitals 444 498 509 584 671
Outpatient Rehabilitation Clinics 810 979 961 996 1 046
Concentra Occupational Health Centers 585 982 1 013 1 558 1 629
Other 1 1 157 190 272
Total Revenues 3 743 4 217 4 365 5 081 5 454
growth % 13% 4% 16% 7%
Organic Revenues 3 159 4 217 4 365 4 592 5 454
Inorganic Revenues 584 489
Cost of Services 3 268 3 665 3 735 4 341 4 641
Gross Profit 474 552 630 740 813
Gross Margin % 13% 13% 14% 15% 15%
G&A 95 107 114 121 128
D&A 105 145 160 202 213
Reported EBITDA 380 445 516 619 684
EBITDA Margin % 10% 11% 12% 12% 13%
Net Income 136 125 221 177 201





2015 2016 2017 2018 2019
Revenues per BU as % of Total Revenues




• SEM’s revenues grew at a CAGR of 9.87%.
• Major source of revenue is Critical Illness, however its
weight on total revenues has been decreasing.
• Regarding payor source, most revenues come from
Commercial Insurance (32%), followed by Medicare
(26%) and Workers’ Compensation (21%).
A
B
• Inorganic revenues: 16% and 10% of revenues are
attributed to acquisitions in 2016 (Concentra) and
2018 (U.S. HealthWorks), respectively.
B
• COS are relevant since SEM operates in a people intensive industry.
• In 2015, around half of the increase in COS resulted from the addition of Concentra, which
operated with a higher relative COS percentage to revenues than Select. The remaining increase
was due to training initiatives, which continued throughout the years, and higher staff turnover.
• In 2018, the increase resulted from the acquisition of U.S. HealthWorks (facility rent expense).
C
C
• SEM’s gross margin has been slightly increasing throughout the years, due to increasing
revenues. However, COS have been increasing as well but with a lower CAGR.
D
• The increase from 2015 to 2016, is due to Concentra
and, from 2016 to 2017, it is due to Physiotherapy.





Note: Please check Appendix II.1. for a more detailed analysis of the Income Statement. Note: in 2019, for comparison purposes, we had to undue the adoption of a new accounting standard on Leases (ASC Topic 842).
Source: Select Medical’s Annual Reports
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Historical Financial Analysis | Statement of Cash Flows
Select Medical’s Free Cash Flow has a CAGR of 191% from 2016 to 2019
Free Cash Flow In $M 2015 2016 2017 2018 2019
EBITDA 380 445 516 619 684
growth % 17% 16% 20% 11%
- Income Taxes 72 55 -18 59 64
growth % -23% -133% -422% 9%
- △NWC -113 171 124 -28 219
growth % 100% -27% -123% -882%
- CAPEX 418 157 163 239 201
growth % -62% 4% 47% -16%
FCF (cash generation) 3 61 247 349 200
growth % 2108% 303% 42% -43%
Cash Flow Statement in $M 2015 2016 2017 2018 2019
Net Income 136 125 221 177 201
+ Non-Cash Items 153 203 114 233 257
+ Changes in Net Working Capital -81 18 -97 84 -13
Cash Flow from Operating Activities 208 346 238 494 445
As % of total Revenues 6% 8% 5% 10% 8%
+ Purchases of PP&E -183 -162 -233 -167 -157
As % of total Revenues 5% 4% 5% 3% 3%
+ Net Payments for Acquisitions -1 063 -396 40 -530 -160
+ Net Payments for Marketable Securities 33 4 0 0 0
Cash Flow from Investing Activities -1 213 -554 -193 -697 -317
As % of total Revenues 32% 13% 4% 14% 6%
+ Debt-related Cash Flows 830 284 -8 574 98
+ Equity-related Cash Flows 184 8 -13 -318 -66
Cash Flow from Financing Activities 1014 292 -22 256 32








• Operating CF has been fluctuating since 2015.
• Partially attributed to oscillations in A/R and in
deferred income taxes.
A
• As a capital-intensive industry such as healthcare,
Select Medical faces slight changes when it comes
to Purchases of PP&E since 2015.
B
• Downward trend in Investing CF.
• Significant increase in 2015 and 2018 due
to acquisitions of Concentra and U.S. HealthWorks.
C
• In 2017, Income Taxes were negative due to effects
resulting from a reform considering federal
legislation on deferred tax liability.
D
• SEM’s Free Cash Flow has been increasing since
2015, except for 2019.
• Mostly due to oscillations in captions that
determine NWC and its investment.







2015 2016 2017 2018 2019
Note: Please check Appendix II.3. for a more detailed analysis of the Statement of Cash Flows. Source: Select Medical’s Annual Reports
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Market Overview | American Healthcare Industry - Segments
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Select Medical Holdings 






























Medical Goods Collective Services and Capital Formation
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• U.S. inpatient care market is expected to grow
at 5.8% CAGR until 2024, accounting for
17.4% of the total healthcare industry in 2019.
• This segment’s growth is restricted by the cost
of U.S. healthcare.
• U.S. outpatient care is expected to grow at
7.07% CAGR until 2024, accounting for 50.8%
of the total healthcare industry in 2024.
• The outpatient care segment is less capital
intensive when compared to others.
• U.S. long term care is expected to grow at
5.42% CAGR until 2024, accounting only 4.8%
of the total industry in 2019.
• However, it accelerated more than any other





















• U.S. medical goods market is expected to grow
at 6.07% CAGR until 2024.
• This segment’s weight in the healthcare
industry is expected to decrease throughout
the years, being around 11.9% in 2024.
• This segment is expected to grow at 6.42%
CAGR until 2024.
• This segment’s weight in total healthcare
expenditures will slightly decrease and
stabilize at 16.2% in 2024.
Inpatient and Outpatient Care are the most relevant segments in the healthcare industry
Main takeaways: 
Source: Marketline “Healthcare providers in the United States”, Select Medical’s reports
Outpatient care is the segment expected to
grow at a faster pace. Also, it is expected that
this segment’s weight increases until 2024.
Inpatient care’s weight on the entire
healthcare industry has increased however,
from 2018 until 2024, it is expected to decline.
The long-term care and medical goods
segments have been constantly decreasing
















545 571 574 596
630
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Investment Thesis
Select Medical’s background and experience allows for superior competitive position
Deal Rationale
Value Creation Strategies
• Select Medical Holdings has the ability to strengthen
its leadership position by adapting to the new context
brought by the pandemic.
• Namely, by diversifying its services portfolio and
offer better and competitive solutions.
• Select Medical can explore new opportunities in the
telemedicine and behavioral health industries
concerning outpatient and occupational therapy,
offering alternatives to patients who are in need and
expand its services’ portfolio, creating a new stream of
revenue for the firm.
• Due to the high level of fragmentation of the
healthcare industry, SEM can acquire and
incorporate strategic players in the market,
improving its competitive positioning and
assure growth.
• The company has a strong track record and
experience in successfully completing and
integrating acquisitions.
• Select Medical can improve its operations
management.
• According to the company’s annual report,
operating performance can be improved at the
acquisitions level, for example, by imposing best
management practices and by realizing
efficiencies, as the activities and management
would be centralized.
• Furthermore, the firm is well positioned to
improve its free cash flow generation and
management.
Operational TurnaroundBolt-on AcquisitionsPortfolio Expansion
• The company portraits
willingness to expand and
acquire new companies in
the future, in order to
consolidate its position.
• Select Medical has proven its
ability regarding the
selection and target
integration of the acquired
firms.
• The success of Select Medical is
based on several competitive
strengths, including the leading
position in each business segments.
• The segments have all been growing
in the past years and present
prospects of profitable growth
mainly due to the company’s strong
reputation and national presence.
• The company presents a track record of
increasing revenues and EBITDA margin.
• Healthy FCF generation which has been
positive and overall increasing
throughout the years and is expected to
continue to deliver such values.
• The company has a leverageable balance
sheet due to a strong asset base (growing
at a CAGR of 9.37%) and a low and
decreasing CAPEX as % of sales.
• Select Medical Holdings is
backed-up by a strong
management team with years
of experience in this industry as
well as in the company.
• Most executives have been on
the firm for several years and
have proven their ability on
leading the company.
Leading market position1 432 Good financial performance Skilled management team Acquisitions experience
Source: Select Medical’s Annual Reports
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Value Creation Strategies | Portfolio Expansion
Through an expansion of the services SEM provides, it can strengthen and improve its leading position
Select Medical Holdings 
Select Medical has a Market leading position which 
can be leveraged and consolidated by expanding
and diversifying its services’ portfolio
Telemedicine
STATUS QUO PORTFOLIO EXPANSION RATIONALE OBJECTIVES
Select Medical should implement the following 
services in its Outpatient/Concentra segments:
Behavioral Health
With these two segments within the services
offering, Select Medical will consolidate its
clients base and attract new clients, which will
lead to a rapid increase in revenues and to a
differentiating advantage among its peers.
Growth of revenues from existing clients
within the new services.
1
Complete and diversify services panoply that
are offered by Select Medical.
2
Attract new clients, creating new revenue
streams.
3
Improvement of competitive advantages
such as the leadership in Outpatient/Concentra
segment.
Within the Outpatient Rehabilitation and Concentra
segments, the following services are provided:
Physical 
Therapy*






















*services that may be adapted to telemedicine





• Higher revenue growth.
• Broader clients base.
• Lower operating costs.
• Consolidation of Select Medical as market leader
in outpatient and occupational segments.
• Higher revenue growth.
• Broader clients base.
• New revenue stream that complements services
already provided.
Acquire adequate software (i.e. app) to be able to:
• conduct online consultations.
• transfer of health history and/or medical records1.
• monitor patients’ health and medical data1.





















In states like Arizona, Colorado, North and South Carolina, SEM
will invest:
• In behavioral healthcare professionals.
• In equipment for specific segments of behavioral health (i.e. autism).




Note: Please check Appendix III.1. and III.2. for detailed analysis of Telemedicine and Behavioral Health strategies.
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Value Creation Strategies | Bolt-on Acquisitions
Select Medical Holdings 
STATUS QUO RATIONALE OBJECTIVES
EXPECTED RESULTSEXECUTION
Bolt-on acquisitions strategy allows for value creation and market consolidation
SEM has successfully been acquiring attractive
targets to consolidate its leadership position as
one of the largest health care providers in the
segments that it operates, based on the number of
facilities and revenues.
• The company’s selective M&A policy aligned
with well-defined acquisition criteria have
been proved successful so far.
• The highly fragmented market of
Outpatient and Concentra offer opportunities
for consolidation and strengthening of Select
Medical’s competitive position.
• The Outpatient segment is growing and has
been little affected by economic downturns.
• The more fragmented the market is, the lower
the negotiating leverage of healthcare
providers. Therefore, consolidation helps SEM
become larger with fewer competitors, which
increases its pricing power over private
insurance companies.
Strengthen the competitive position and expand
the portfolio, increase revenues, reduce
operational and fixed costs (economies of scale),
and acquire a stronger ability to navigate the
uncertainty surrounding the future of healthcare.
1 Value creation
• Acquire companies with strong cash flows and
revenue growth in order to improve Select
Medical’s revenues through cross-selling and
enlargement of the customer base.
• Allow Select Medical to continue to provide
care for its patients after being discharged
from critical care.
• Improve operating margins through cost
synergies obtained with the acquisitions.
Consolidate market position
• Obtain significant position in the
Outpatient segment, which is growing faster
than any other segment.
• Expand the portfolio of segments in which
Select Medical is present.
• Become an even more significant national
player in the healthcare sector.
• Acquire two pre-selected targets, which are located across the U.S..
• Formulating and executing an integration plan for the acquired 
companies to benefit from cost synergies and larger client base. 
• Additional inorganic EBITDA between 2020 and 2025 of more than 
$300M.
• Expansion of portfolio and cost related synergies. 
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Competitive position & Portfolio expansion
• Market divisions across the U.S. provide
opportunities for M&A in order to increase
SEM’s market share.
• Acquiring companies with expertise in other
health care segments allows rapid entrance in
new profitable segments.
Revenues growth
• Integrating new companies improves organic
sales growth in the following years after
acquisition.
Economies of scale
• SEM’s fixed costs are large and horizontal
expansion can spread those costs across a
greater volume of patients.
2
Source: Company’s annual reports and website and Marketline “Healthcare providers in the United States” 
Drive growth of operating margins towards peers’
values through efficiency enhancements measures.
2019 2020 2025
2015 2016 2017 2018 2019
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Value Creation Strategies | Operational Improvement
Enhanced profitability through the implementation of an ERP system and use of innovative technologies  
Select Medical Holdings 











• Cease operations in less efficient facilities and
in states with lower reimbursement rates.
• Cost cutting and efficiency gains through the
implementation of better operating systems.
• Use of innovative technologies in the facilities.
SEM’ management team has been centralizing key
administrative services in order to improve operating
efficiency and control costs. Cease facilities
• Decrease the number of less efficient clinics in
states with lower reimbursement rates (Florida
and Texas which also have a higher percentage
of uninsured population) and also due to the
introduction of telemedicine.
• Assess states with higher number of outpatient clinics and lower
reimbursement rates to cease less efficient facilities.
• Implement ERP in current and acquired facilities, increasing
productivity and efficiency and providing management with
better tools to assess operating performance.
• Implement advanced robotics in inpatient rehabilitation clinics.
• Profitability margins closer to peers’, becoming more competitive.
• Maximized efficiency throughout facilities and faster incorporation of
acquired companies or facilities.
• Improvement of service quality through better management services
which allow physicians to provide better care.
• Development of provided care through the use of innovative technologies.
1 Increase operating margins
2 Increase revenues through new patients
• The ERP implementation allows for better
management and providing better patient care,
increasing quality and attracting patients.
• Innovative technologies contribute to a faster
rehabilitation and patients’ engagement,
increasing the quality of the service provided.
Take an insightful look into the company’s operating
performance and take advantage of technology to
improve SEM’s performance.
Innovative technologies
• Provide first-class service and care to assist
and contribute to patients’ recovery.
Implementation of ERP system
• Through ERP, Select Medical will have a more
detailed and wholesome knowledge of the
company’s financial and operating performance.
11






Note: Please check Appendix III.4 for detailed analysis of Operational Improvement. Source: Select Medical’s Annual Reports and website
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Business Plan | Overview of Main Drivers
With strategic acquisitions and costs improvement, SEM is set for a high growth path in the next 6 years
Select Medical Holdings 











3 Net Working Capital
Select Medical will be acquiring two other small
strategic companies. These will allow to:
• Add revenues of $953M at exit.
• Enter the respiratory services and post-
acute care segments, which both yield high
revenues.
• Increase SEM’s geographical presence.
Main drivers of SEM’s organic growth:
• Growth of SEM’s on-facility services, and
telemedicine services especially in Outpatient
and Concentra segments, almost in line with
each segment’s market growth.
• The most relevant segments within the organic
revenues are Concentra Occupational Health
Centers and Critical Illness Recovery Hospital.
• COS are expected to grow at a CAGR1 of 6.90%.
• SEM will benefit from synergies due to acquisitions (we
expect supplies expense to decelerate its growth by
1.25% per year from one year after the first acquisition
onwards), and the operational turnaround will allow it
to close the less profitable facilities.
• However, portfolio expansion strategy will not allow
COS to slow down as much since more healthcare
professionals will be employed.
Even though it remains constant at 3% of
Revenues, Maintenance CAPEX faces an increase
of $113M from 2019 to 2025 due to strategies
and equipment2 to achieve target revenues.
The Expansion CAPEX is stable as percentage of
total revenues. However, in 2020 and 2022 it will
significantly increase due to acquisitions that
will contribute with $88M in EBITDA at exit, in
2025. Acquisitions will be financed using 50% of
CAPEX facility and 50% of cash.
Net Working Capital is constantly increasing
during the entire investment period due to a
general increase in all current assets, especially
cash and cash equivalents.
% of RevenuesIn $M
2- Includes Equipment of SEM, Viemed and Diversicare
5 454 5 749 6 075 6 459
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2019 2020 2021 2022 2023 2024 2025 2026
Maintenance CAPEX Net Working Capital
2
1
1- From 2020 to 2025
G&A: It is expected to increase in 2020 due to investment
in ERP system. However, from 2021 to 2025, it will
decelerate its growth fulfilling cost-efficiencies.
D&A: its YoY growth is fairly stable however, in 2020 and
2022 it increases due to the acquisitions of Viemed (6%)
and Diversicare (11%), accordingly.
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Exit & Returns | Capital Structure
Select Medical Holdings 
Total leverage of 5.5x EBITDA and an equity contribution of 9.8x EBITDA for SEM’s acquisition
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Uses of Funds
• Total uses of funds, totalling $10,446m, are destined
to pay for EV of $10,134m and the remaining
amount is for financing fees and other fees and
expenses related to the transaction.
• Enterprise Value is based on a EV/EBITDA multiple
of 14.81x estimated in the valuation section.
Sources of Funds
• Total uses of funds are sourced from an equity
contribution of 9.8x EBITDA ($6,681m) and
leverage of 5.5x EBITDA ($3 765m).
• For the debt portion of the sources, there are three
tranches of senior debt and mezzanine debt. All of
the mentioned are contracted in U.S. dollars and
non-amortizing for tranches B and C and mezzanine.
• The equity contribution is composed of a fixed
return instrument of $6,481m and ordinary equity
of $190m.
• Top management will hold $10m worth of shares
(sweet equity), which is twice their combined annual
compensation, and also $45m of FRI and $1m of
ordinary equity, in order to align interests.
Other
• A CAPEX Facility of $236m will be used to partially
finance the planned acquisitions throughout the
investment period.
• Three potential capital structures were
analyzed so as to compare returns at exit
Capital structure 1 is the preferred as
Capital Structure 2 delivers a slightly lower
money multiple at exit and the leverage
multiple is the same.
• Capital Structure 3 requires the lowest
amount of debt, and yields the lowest MM.
Note: Please check Appendix IV.4, IV.5, IV.6 for detailed capital structures in different scenarios and IV.7 for detailed financing structures. 
CommentsAmount % xEBITDA Pricing Amount %
Term Loan A - - - L + 375 bps Equity Purchase $7 025 67.3%
Term Loan B $2 053 19.7% 3.0x L + 400 bps Repay Existing Debt $3 109 29.8%
Term Loan C $1 027 9.8% 1.5x Financing Fees $210 2.0%
Mezzanine $684 6.6% 1.0x Other Fees and Expenses $101 1.0%
PIK Element 600 bps
Cash Element L + 675 bps
Institutional Strip
PE Fund
Fixed Return Inst. $6 435 61.6% 9.4x 1250 bps
Institutional Ords $189 1.8% 0.3x
Total $6 624 63.4% 9.7x
Management
Fixed Return Inst. $46 0.4% 0.1x 1250 bps
Institutional Ords $1 0.0% 0.0x
Total $10 0.1% 0.0x
Sweet Equity $57 0.5% 0.1x
Total Sources $10 446 100% 15.3x Total Uses $10 446 100%
Instrument Structure 1 Structure 2 Structure 3
Senior Tranche A - $856 -
Senior Tranche B $2 053 $1 027 $1 711
Senior Tranche C $1 027 $1 027 $1 027
Mezzanine $684 $856 $684
Equity Contribution $6 681 $6 681 $7 024
Leverage 5.5x 5.5x 5.0x
MM at Exit 3.03x 3.02x 2.95x
0 5 000 10 000 15 000 20 000 25 000
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Exit & Returns | Entry Valuation
Select Medical Holdings 
Through the football field analysis with several methodologies, a 14.81x EV/EBITDA multiple was achieved
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Comments
• Sources: Bloomberg and Reuters.
• The minimum value for the multiple was 11.39x whilst
the maximum was 27.08x, suggesting a big gap
between valuations.























• Precedent transactions were selected from Reuters
industry sector.
• As seen in the previous methodology, there is also a
large interval between minimum and maximum
multiples, 5.70x to 24.99x.
• Overall, multiples of comparable companies have been
increasing throughout the years however, 2018, seemed
to be the year with the highest multiples.
• The minimum multiple was 8.49x (2016) and the
maximum was 27.54x (2018).
• The share prices 1 day, 1 week and also 1 month prior to
acquisition (of the same companies as in precedent
transactions) were analyzed.
• The premium was applied to SEM’s share price prior
to acquisition.
• For the DCF, WACC was estimated based on the
company’s latest bond issues and recent information.
The terminal growth rate ranged from 1.0% to 1.5%.




Note: Please check Appendix IV.1, IV.2 and IV.3 for detailed methodology analysis.
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Exit & Returns | Returns Breakdown
Select Medical Holdings 
RETURNS BREAKDOWN
Select Medical’s strong margin evolution and revenue growth will drive a Money Multiple of 3.03x
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• The Revenue Growth is the most
important return driver in the
Investment Case, contributing with
0.86x in terms of multiples.
• This is obtained due to the business
strategy of implementing new
revenue streams and of
accomplishing new acquisitions.
Revenue Growth Margin Evolution Deleveraging
Entry & Exit Fees
Multiple Arbitrage
• The Margin Evolution is the
second most important return
driver in the Investment Case,
contributing with 0.82x in terms of
multiples.
• This is obtained due to the high
revenue growth throughout the
investment period and due to the
efficiency gains predicted in the
business plan.
• The Deleveraging is the third most
important return driver in the
Investment Case, contributing with
0.23x in terms of multiples.
• This is obtained mostly due to the
demanding and well-established
debt repayment schedule but also
due to the great performance that
is expected from Select Medical.
• The Multiple Arbitrage is expected to
have a null impact on the returns as
the U.S. economy will face many
challenges in the near future.
• The Entry & Exit Fees will play a
















Entry Equity Entry Fee Revenue Growth Margin Evolution Multiple Arbitrage Deleveraging Exit Fees Exit Equity
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Exit Strategy | Exit Options
Select Medical Holdings 
Strategic Sale
Strategic sale is the most favorable exit option for the Private Equity Fund
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• Healthcare is highly fragmented
in the U.S. and there are
significant consolidation efforts
in the market, leading to several
interested buyers and a strong
competition.
• There are larger healthcare
companies with resources to
acquire SEM and gain synergies.
• Despite the crisis created by the
ongoing pandemic, there has
been M&A activity in the
healthcare industry among PE
funds.
• Private Equity funds had around
$2 trillion of dry-powder as of
July 2020.
• An IPO would allow Select
Medical to have access to a
larger market when comparing
with the remaining exit options.
• Considering the size of the
company, it is a good potential
candidate for this exit strategy.
• Potential buyers might only be
interested in some segments of
the company.
• Some business segments are
growing at a faster rate than
others.
• Depending on the situation, the
transaction might be a slow
process.
• There is the possibility that
investors are in both the buyers’
and seller’s funds thus, not
getting liquidity and end up
investing in the same company.
• Other PE firms may believe the
efficiencies have been explored
to their maximum.
• This strategy relies on the
current capital market
conditions and is generally more
expensive.
• With the current COVID-19 crisis,
there is still uncertainty
regarding forecasts and
prospects for the markets in
2024, increasing risk.
• This exit strategy leads to the
loss of synergies created
throughout the investment
period.
• Might lead to longer process
since it would require several
buyers.
Source: PwC
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Exit Strategy | Key Due Diligence Areas
Select Medical Holdings 
Area
Important areas such as Commercial and Financial must be further explored for a successful transaction 
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• How dependent is the market growth from macroeconomic
conditions
• Examination of genuine strength of significant patterns during
the next 5 years for each segment where SEM operates
• Economic crisis materially impacting the forecasts,
affecting revenues
• Overestimation of positive outlook in target markets
• Future market trends that SEM is not capable of
supplying
• Identify the type of patients that most utilize SEM’s services
• Evaluate if there are patients that were lost in the recent years
and why it happened
• High dependency on some types of patients
• Considerable number of unsatisfied patients
• Thoroughly analyze the acquisition targets (specially margins,
growth prospects and synergies)
• Inability to follow the acquisition strategy due to
difficult integration and/or unrealistic synergies
• Detailed analysis of competitors per service and location
• Compare SEM’s competitive advantages with the competitors’
• Inability to outperform the market
• Competitors being able to replicate SEM’s business
model and service quality
• Evaluation of the efficiencies and cost reductions obtained with
the implementation of ERP system
• ERP system implementation takes a long time and
generates more costs than benefits on the ST.
• Explore in detail and question some of SEM’s current suppliers
• Assess post-integration synergies after targeted acquisitions
• High dependence on a few suppliers can difficult
the operational turnaround strategy
• Perform an in-depth financial statement analysis (revenue and
cash-flow generation, debt valuation assumptions, evaluate
Goodwill and PP&E to assess any necessary impairments)
• Accounting frauds (overstating revenues,
unrecorded expenses, misstatement of assets and
liabilities)
• Evaluate facilities’ utilization rates & capacity to foster growth
• Compare the leasing of facilities strategy with their ownership
• It is difficult to increase the nr. of services offered at
current facilities if they are at maximum capacity
• Verify compliance with environmental policies, assess insurance
coverage, and any tax-related case pending with tax authorities
• Lack of proactive ESG actions, inappropriate
insurance coverage
• Appraisal of pending pension plan payments • Large expected losses due to future settlements
Select Medical Holdings
Investment Committee Paper
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• SEM was co-founded by Rocco A. Ortenzio and Robert A. Ortenzio in 1996.
• Initially it was a local provider of outpatient physical rehabilitation. In 1997, Select Medical started offering contract therapy and later it introduced long-term
acute care in 1998.
• In 1999, SEM made one of its largest acquisitions: NovaCare Physical Rehabilitation and Occupational Health.
• Due to the company’s liable growth strategy, Forbes recognized it as one of the “Best Managed Companies in America”.
• In 2001, Select Medical entered the public market and was listed on NASDAQ and later, it was listed on the NYSE (where it is currently traded).
• In 2004, the company acquired the world-prestigious Kessler Institute for Rehabilitation which allowed it to have clinical and operational growth and add
inpatient medical rehabilitation to its care offerings. Nowadays, these care lines continue to grow through joint ventures and partnerships with some of the most
well-acclaimed companies in the industry.
“Select Medical will provide an exceptional patient care experience that promotes healing and recovery in a compassionate environment”
“We deliver superior quality in all that we do.”
“We treat others as they would like to be treated.”
“We are results-oriented and achieve our objectives.”
“We are team players.”
“We are resourceful in overcoming obstacles.”
Areas of Expertise
• Critical Illness Recovery 
• Inpatient Medical Rehabilitation 
• Outpatient Physical Therapy
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10 Joint Commission Disease
accreditations, including: stroke,
brain injury and amputee.
22 CARF accreditations,
including stroke, spinal cord
injury, brain injury, amputee
and outpatient services.
1These accreditations are awarded to hospitals or clinics that Select 
Medical owns.








• Focus on Specialized Inpatient Services and Occupational Medicine and
expand Rehabilitation programs.
• Provide high-quality care to patients and their families, controlling operating
costs and increase volume and market share.
• Expand Rehabilitation Hospitals through the pursuit of Joint Ventures and
optimize payor contract reimbursements.
Company Overview | Business Model
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To strengthen a market leading position, SEM is backed by strong competitive advantages and key strategies
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The partnerships aim to advance health care across the U.S. and provide better 
service for patients and their families. 
Source: Select Medical’s Annual Report 2019, BloombergAppendix I.1 for detailed competitive advantages
• Costs of Services includes the cost of healthcare professionals (44%), all the
materials required for their job (14%), lease and rent expense (6%) and other
operating costs (21%).
• G&A and D&A have been growing as Select Medical continues to grow its
revenues. Despite the continuous growth of D&A, this caption is only relevant
due to the amount of CAPEX that the company has and its growth. For more
information, please check Financials.
93.15%COS G&A 2.58% D&A 4.27% 
• CAPEX represent a significant portion of investments of SEM but have overall
been decreasing throughout the years as the company matures (11.2% of
revenues in 2015 and 3.7% of revenues in 2019).
• Both Expansion CAPEX and Maintenance CAPEX contribute to revenues’
growth. In 2016, Total CAPEX decreased 62.4%, and therefore revenues in 2017
grew only 3.5%, whilst in 2018 Total CAPEX grew 46.6%, and revenues grew
16.4% in that year.
• Expansion CAPEX represented 77.0%, 17.9%, and 28.1% of Total CAPEX in
2015, 2016, and 2018, respectively, due to the acquisition of Concentra,
Physiotherapy, and U.S. HealthWorks, in each year accordingly.
• Leading medical company in each 
area of expertise
• Proven financial performance
• Strong cash flow generation
• Significant size and scale
• Strong national presence 
• Background in completing and 
integrating acquisitions
• Partnerships with large healthcare 
players





















Rocco A. Ortenzio Robert A. Ortenzio
Mr. Rocco has served as Vice Chairman
and Co-founder while Mr. Robert has
served as Executive Chairman and Co-
founder since January 2014. Both served as
CEOs in the past.
Mr. Rocco founded other medical
institutions in which he served as CEO and
director.
Mr. Robert serves on the Board of
Directors of Concentra Group Holdings
Parent and served as an Executive Vice
President and a director of other medical
institutions.
David Chernow
Mr. Chernow has served as President and
CEO since January 1, 2014. He held various
executive officer titles since 2010. Before
2010, he was on several medical
institutions’ management teams.
Martin Jackson
Mr. Jackson has served as Executive Vice
president and CFO since February 2007.
He also serves on the board of Concentra
Group Holdings Parent. Previously, he
served on other medical institutions.
John Saich
Mr. Saich has served as Executive
Vice President and CAO since
October 2018. He joined the
company in 1998 as Director, Human
Resources and HRIS.
Michael Tarvin
Mr. Tarvin has served as Executive
Vice President, General counsel and
Secretary since February 2007. He
joined the company in 1997 after
serving as Senior Counsel of a
medical firm.

























All members had previous background in the medical and healthcare
industry before entering the Board of Directors at Select Medical
Holdings. Also, most of the directors are also chairman at other
medical institutions and organizations.
Company Overview | Management Overview
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SEM’s management team has extensive experience, with almost 25 years in the business
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Source: Select Medical’s Annual Report 2019 and website
Every healthcare professional working for Select Medical is
required, under applicable state law, to be licensed or
certified. The company takes all the necessary measures to
ensure all employees and agents have the necessary licenses
and/or certifications.
Nova School of Business and Economics | Private Equity Challenge
Market Overview | U.S. Healthcare Industry and SEM’s Business Segments
Select Medical Holdings 
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Inpatient Care Outpatient Care
Critical Illness Recovery 
Hospitals





• Occupational medicine is related to
the treatment of work-related
injuries and illnesses.
• Market value of $7.7B (2019).
• Between 2014 and 2019, CAGR of
2.4%.





• Low revenue volatility
• Government consumption and
investment
• Increasing number of employees
in the U.S. creates higher demand
• Growth of an unhealthy lifestyle
• Increasing older population
• Cost-effectiveness
• Improvements in science and
technology reduce recovery time
and shift inpatient to outpatient
Pay
• In most states of the U.S., employers
are required to provide Workers’
Compensation Insurance which
covers for injuries on the job or work-
related illnesses.
• In 2015, the average annual cost per
employee was $11 750 and in 2019
it was $13 087. The incident rate has
been declining except in 2018.
• Outpatient care (or ambulatory care)
does not require hospitalization.
• U.S. outpatient rehabilitation market
is estimated to value around $30B
with a projected annual growth
rate of around 5%.
• Increased health insurance coverage
• Growth of an unhealthy lifestyle
• Growth of aging population
• Growth of chronic illnesses (6/10 U.S. adults have a chronic
disease and 4/10 U.S. adults have two or more)
• Medicare Part B covers for 80% of
costs, the patient covers 20%.
• Rehabilitative services are not
necessarily covered by Medicaid
on all states.
• Largest payor are private insurance
companies (45%) followed by
government programs (38%) and
Employee insurance (14%).
• Critical Illness Recovery Hospitals treat chronic illnesses and
Rehabilitation Hospitals treat patients who suffered an injury.
• Inpatient care segment represents 17.4% of U.S. Healthcare
market, being its market value $664B.
• Relatively low density of hospital beds per population (2.8
beds per 1,000 people in 2015), suggests a need for new
healthcare providers in order to improve inpatient care.
• Medicare Part A covers hospital charges and most services a
patient receives while on the hospital. Most people do not have
to pay a monthly premium for this insurance.
• Medicaid covers for inpatient hospital services.
• From 2007 to 2015, Medicaid was the top payer for patients
under age 18 years.
• Among patients with 65 years or more, Medicare and private
insurance accounted for around 97% of inpatients stays.
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Market Overview | Healthcare Value Chain
Select Medical Holdings plays a key role on the healthcare industry value chain as a service provider
Healthcare Value Chain
1 2 3 4 5
Value Chain Players
Uninsured population is a major
barrier to even higher levels of
growth.
Federal data showed that the number
of uninsured people in the U.S. was
close to 8% of the population in
2019.
Complexity of U.S. healthcare industry
Less Purchasing Power
Uninsured population














Some producers are: pharmaceutical
companies, device manufacturers
surgical products companies, and
manufacturers of information
















As providers there are: hospitals,
integrated delivery networks, and
alternate site facilities (physician





































Among distributors there are
independent contracted distributors,
pharmaceutical wholesalers, surgical
equipment distributors, and product
representatives employed by
manufacturers.
Private health insurance coverage was
68% and public coverage was 34.1%.
In 2019, the percentage of people with
employer-provided coverage was
slightly higher than in the previous year,
from 55.2% to 55.4% (at the time of the
interview).
Source: U.S. Census Bureau “Health Insurance Coverage in the United States: 2019”, “The Wharton School Study of the Healthcare value chain”  
2019 Type of Coverage Poverty level, race and ethnicity and age,
make some people more vulnerable to the
state of uninsured, as reported in a study
conducted by Kaiser Family Foundation.
The percentages of Blacks and Hispanics
without health insurance coverage for the
entire year were higher than for non-
Hispanic Whites, at 9.6% and 16.7%,
respectively.
*Note: some individuals will pay directly to the provider 
without the need of fiscal intermediaries
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Personal Reflection | COVID-19 and its impact on the PE industry
COVID-19 disrupted the PE industry and firms are focused on protecting their portfolios
Sources: “A rolling disruption: COVID-19’s implications for private equity and portfolio companies”, McKinsey & Company; “The impact of Covid-19 on Private Equity”, Bain & Company
• COVID-19 brought disruption to the Private Equity market, forcing companies to adapt to the current macroeconomic context.
• PE firms are focusing on salvaging part of their portfolios as well as uncovering sustainable emerging trends, showing concern over what will succeed in
postpandmic markets.
• Central Banks have injected around $9 trillion into financial assets, helping equity markets to face the crisis.
Overview of the current situation:
Portfolio Exposures
• PE companies have almost $6 trillion in assets under management.
• Over 95% of those AUM is focused on 20 sectors and subsectors.
Furthermore, real estate, business and professional services, energy and
utilities, industrial equipment and machinery, software and healthcare
account for more than 50% of that.
• As of March 2020, global market capitalization in all sectors had been
negatively impacted by the current crisis. However, as of July 2020, it has
recovered in some sectors: Pharma and biotech, software, healthcare, etc.
Investments
• While GPs are concerned for their
portfolios, sellers are hesitant
and disinclined to sell their
assets due to the decline in
equity values.
• Regarding credit markets, banks
are putting lending on hold for
new deals so as to concentrate
on current borrowers and avoid
defaults.
Lenders will need to learn how to 
assess risk differently and 
incorporate similar events.
Scrutiny in the underwriting process 
is expected to increase.
Leverage multiples will decrease
and buyers will have to contribute 
with more equity.
However, while this might lead to less
activity, dealmaking can increase
since PE funds have $2.5 trillion of
dry powder thus, GPs will be looking
for new deals.
Furthermore, private debt funds
might provide financing for new deals.
Exits
• Exits are expected to decline and thus, investment periods are likely to
extend since sellers will be waiting for markets to recover.
Fund-raising
• Fund-raising is not expected to be as impacted as it was during the global
financial crisis of 2008 because, since then, investors increased PE allocations
expecting higher returns in comparison to public markets, in the long-term.
• However, fund-raising can be constrained since industry capital calls will
exceed distributions, because a decline in exits slows down payouts to LPs,
causing liquidity problems for them.
• Overall, LPs are expected to be more selective with their investments.
Returns
In the short-term, returns will likely
decrease due to declining valuations.
Nevertheless, in the long-term,
valuations are expected to stabilize
when public markets do, leading returns
to bounce to pre-pandemic values.
24
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